|
| | SB1810 Engrossed | - 2 - | LRB099 00139 KTG 20139 b |
|
|
|
| 1 | | emergency services and the cost impact of emergency |
| 2 | | services utilization. |
| 3 | | (D) Suggested improvements in data collection. |
| 4 | | (E) A description of other interventions effective |
| 5 | | in reducing the rate of fatal or nonfatal drug |
| 6 | | overdose. |
| 7 | | (b) Programs; drug overdose prevention. |
| 8 | | (1) The Director may establish a program to provide for |
| 9 | | the production and publication, in electronic and other |
| 10 | | formats, of drug overdose prevention, recognition, and |
| 11 | | response literature. The Director may develop and |
| 12 | | disseminate curricula for use by professionals, |
| 13 | | organizations, individuals, or committees interested in |
| 14 | | the prevention of fatal and nonfatal drug overdose, |
| 15 | | including, but not limited to, drug users, jail and prison |
| 16 | | personnel, jail and prison inmates, drug treatment |
| 17 | | professionals, emergency medical personnel, hospital |
| 18 | | staff, families and associates of drug users, peace |
| 19 | | officers, firefighters, public safety officers, needle |
| 20 | | exchange program staff, and other persons. In addition to |
| 21 | | information regarding drug overdose prevention, |
| 22 | | recognition, and response, literature produced by the |
| 23 | | Department shall stress that drug use remains illegal and |
| 24 | | highly dangerous and that complete abstinence from illegal |
| 25 | | drug use is the healthiest choice. The literature shall |
| 26 | | provide information and resources for substance abuse |
|
| | SB1810 Engrossed | - 3 - | LRB099 00139 KTG 20139 b |
|
|
|
| 1 | | treatment. |
| 2 | | The Director may establish or authorize programs for |
| 3 | | prescribing, dispensing, or distributing naloxone |
| 4 | | hydrochloride or any other similarly acting and equally |
| 5 | | safe drug approved by the U.S. Food and Drug Administration |
| 6 | | for the treatment of drug overdose. Such programs may |
| 7 | | include the prescribing of naloxone hydrochloride or any |
| 8 | | other similarly acting and equally safe drug approved by |
| 9 | | the U.S. Food and Drug Administration for the treatment of |
| 10 | | drug overdose to and education about administration by |
| 11 | | individuals who are not personally at risk of opioid |
| 12 | | overdose. |
| 13 | | (2) The Director may provide advice to State and local |
| 14 | | officials on the growing drug overdose crisis, including |
| 15 | | the prevalence of drug overdose incidents, trends in drug |
| 16 | | overdose incidents, and solutions to the drug overdose |
| 17 | | crisis. |
| 18 | | (c) Grants. |
| 19 | | (1) The Director may award grants, in accordance with |
| 20 | | this subsection, to create or support local drug overdose |
| 21 | | prevention, recognition, and response projects. Local |
| 22 | | health departments, correctional institutions, hospitals, |
| 23 | | universities, community-based organizations, and |
| 24 | | faith-based organizations may apply to the Department for a |
| 25 | | grant under this subsection at the time and in the manner |
| 26 | | the Director prescribes. |
|
| | SB1810 Engrossed | - 4 - | LRB099 00139 KTG 20139 b |
|
|
|
| 1 | | (2) In awarding grants, the Director shall consider the |
| 2 | | necessity for overdose prevention projects in various |
| 3 | | settings and shall encourage all grant applicants to |
| 4 | | develop interventions that will be effective and viable in |
| 5 | | their local areas. |
| 6 | | (3) The Director shall give preference for grants to |
| 7 | | proposals that, in addition to providing life-saving |
| 8 | | interventions and responses, provide information to drug |
| 9 | | users on how to access drug treatment or other strategies |
| 10 | | for abstaining from illegal drugs. The Director shall give |
| 11 | | preference to proposals that include one or more of the |
| 12 | | following elements: |
| 13 | | (A) Policies and projects to encourage persons, |
| 14 | | including drug users, to call 911 when they witness a |
| 15 | | potentially fatal drug overdose. |
| 16 | | (B) Drug overdose prevention, recognition, and |
| 17 | | response education projects in drug treatment centers, |
| 18 | | outreach programs, and other organizations that work |
| 19 | | with, or have access to, drug users and their families |
| 20 | | and communities. |
| 21 | | (C) Drug overdose recognition and response |
| 22 | | training, including rescue breathing, in drug |
| 23 | | treatment centers and for other organizations that |
| 24 | | work with, or have access to, drug users and their |
| 25 | | families and communities. |
| 26 | | (D) The production and distribution of targeted or |
|
| | SB1810 Engrossed | - 5 - | LRB099 00139 KTG 20139 b |
|
|
|
| 1 | | mass media materials on drug overdose prevention and |
| 2 | | response. |
| 3 | | (E) Prescription and distribution of naloxone |
| 4 | | hydrochloride or any other similarly acting and |
| 5 | | equally safe drug approved by the U.S. Food and Drug |
| 6 | | Administration for the treatment of drug overdose. |
| 7 | | (F) The institution of education and training |
| 8 | | projects on drug overdose response and treatment for |
| 9 | | emergency services and law enforcement personnel. |
| 10 | | (G) A system of parent, family, and survivor |
| 11 | | education and mutual support groups. |
| 12 | | (4) In addition to moneys appropriated by the General |
| 13 | | Assembly, the Director may seek grants from private |
| 14 | | foundations, the federal government, and other sources to |
| 15 | | fund the grants under this Section and to fund an |
| 16 | | evaluation of the programs supported by the grants. |
| 17 | | (d) Health care professional prescription of drug overdose |
| 18 | | treatment medication. |
| 19 | | (1) A health care professional who, acting in good |
| 20 | | faith, directly or by standing order, prescribes or |
| 21 | | dispenses an opioid antidote to a patient who, in the |
| 22 | | judgment of the health care professional, is capable of |
| 23 | | administering the drug in an emergency, shall not, as a |
| 24 | | result of his or her acts or omissions, be subject to |
| 25 | | disciplinary or other adverse action under the Medical |
| 26 | | Practice Act of 1987, the Physician Assistant Practice Act |
|
| | SB1810 Engrossed | - 6 - | LRB099 00139 KTG 20139 b |
|
|
|
| 1 | | of 1987, the Nurse Practice Act, the Pharmacy Practice Act, |
| 2 | | or any other professional licensing statute. |
| 3 | | (2) A person who is not otherwise licensed to |
| 4 | | administer an opioid antidote may in an emergency |
| 5 | | administer without fee an opioid antidote if the person has |
| 6 | | received the patient information specified in paragraph |
| 7 | | (4) of this subsection and believes in good faith that |
| 8 | | another person is experiencing a drug overdose. The person |
| 9 | | shall not, as a result of his or her acts or omissions, |
| 10 | | except for willful and wanton misconduct, be liable for |
| 11 | | civil damages, and shall not, as a result of his or her |
| 12 | | acts or omissions, be liable for any violation of the |
| 13 | | Medical Practice Act of 1987, the Physician Assistant |
| 14 | | Practice Act of 1987, the Nurse Practice Act, the Pharmacy |
| 15 | | Practice Act, or any other professional licensing statute, |
| 16 | | or subject to any criminal prosecution arising from or |
| 17 | | related to the unauthorized practice of medicine or the |
| 18 | | possession of an opioid antidote. |
| 19 | | (3) A health care professional prescribing an opioid |
| 20 | | antidote to a patient shall ensure that the patient |
| 21 | | receives the patient information specified in paragraph |
| 22 | | (4) of this subsection. Patient information may be provided |
| 23 | | by the health care professional or a community-based |
| 24 | | organization, substance abuse program, or other |
| 25 | | organization with which the health care professional |
| 26 | | establishes a written agreement that includes a |
|
| | SB1810 Engrossed | - 7 - | LRB099 00139 KTG 20139 b |
|
|
|
| 1 | | description of how the organization will provide patient |
| 2 | | information, how employees or volunteers providing |
| 3 | | information will be trained, and standards for documenting |
| 4 | | the provision of patient information to patients. |
| 5 | | Provision of patient information shall be documented in the |
| 6 | | patient's medical record or through similar means as |
| 7 | | determined by agreement between the health care |
| 8 | | professional and the organization. The Director of the |
| 9 | | Division of Alcoholism and Substance Abuse, in |
| 10 | | consultation with statewide organizations representing |
| 11 | | physicians, advanced practice nurses, physician |
| 12 | | assistants, substance abuse programs, and other interested |
| 13 | | groups, shall develop and disseminate to health care |
| 14 | | professionals, community-based organizations, substance |
| 15 | | abuse programs, and other organizations training materials |
| 16 | | in video, electronic, or other formats to facilitate the |
| 17 | | provision of such patient information. |
| 18 | | (4) For the purposes of this subsection: |
| 19 | | "Opioid antidote" means naloxone hydrochloride or any |
| 20 | | other similarly acting and equally safe drug approved by |
| 21 | | the U.S. Food and Drug Administration for the treatment of |
| 22 | | drug overdose. |
| 23 | | "Health care professional" means a physician licensed |
| 24 | | to practice medicine in all its branches, a physician |
| 25 | | assistant who has been delegated the prescription or |
| 26 | | dispensation of an opioid antidote by his or her |
|
| | SB1810 Engrossed | - 8 - | LRB099 00139 KTG 20139 b |
|
|
|
| 1 | | supervising physician, an advanced practice registered |
| 2 | | nurse who has a written collaborative agreement with a |
| 3 | | collaborating physician that authorizes the prescription |
| 4 | | or dispensation of an opioid antidote, or an advanced |
| 5 | | practice nurse who practices in a hospital or ambulatory |
| 6 | | surgical treatment center and possesses appropriate |
| 7 | | clinical privileges in accordance with the Nurse Practice |
| 8 | | Act. |
| 9 | | "Patient" includes a person who is not at risk of |
| 10 | | opioid overdose but who, in the judgment of the physician, |
| 11 | | may be in a position to assist another individual during an |
| 12 | | overdose and who has received patient information as |
| 13 | | required in paragraph (2) of this subsection on the |
| 14 | | indications for and administration of an opioid antidote. |
| 15 | | "Patient information" includes information provided to |
| 16 | | the patient on drug overdose prevention and recognition; |
| 17 | | how to perform rescue breathing and resuscitation; opioid |
| 18 | | antidote dosage and administration; the importance of |
| 19 | | calling 911; care for the overdose victim after |
| 20 | | administration of the overdose antidote; and other issues |
| 21 | | as necessary.
|
| 22 | | (Source: P.A. 96-361, eff. 1-1-10.)
|
| 23 | | Section 99. Effective date. This Act takes effect upon |
| 24 | | becoming law.
|